
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Forecast Data Period | 2025 - 2030 |
Historical Data Period | 2019 - 2023 |
Market Size (2025) | USD 17.55 Billion |
Market Size (2030) | USD 32.51 Billion |
CAGR (2025 - 2030) | 13.13 % |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
North America Blood Glucose Monitoring Market Analysis
The North America Blood Glucose Monitoring Market size is estimated at USD 17.55 billion in 2025, and is expected to reach USD 32.51 billion by 2030, at a CAGR of 13.13% during the forecast period (2025-2030).
The blood glucose monitoring industry continues to evolve rapidly, driven by technological advancements and changing healthcare needs. According to recent statistics, approximately 1.5 million Americans receive new diabetes diagnoses annually, highlighting the growing need for effective monitoring solutions. The industry has witnessed significant innovation in device connectivity, with manufacturers increasingly incorporating smart glucose monitoring features and cloud-based data management capabilities. These technological improvements have enhanced the ability of healthcare providers to remotely monitor patient data and make more informed treatment decisions, leading to better patient outcomes and increased adoption of modern monitoring devices.
The market landscape is experiencing a transformation through the introduction of more affordable and accessible monitoring solutions. In 2022, Abbott introduced a new lower-priced category with Libre, priced between USD 75 to USD 150 per month, making continuous glucose monitoring more accessible to a broader patient base. This trend towards affordability has been complemented by expanding insurance coverage, with notable developments such as Ontario's implementation of CGM coverage through its Assistive Devices Program in March 2022, benefiting eligible residents with type 1 diabetes.
The adoption of continuous glucose monitoring (CGM) systems has seen remarkable growth, with approximately 90% of Type-1 diabetic patients in developed countries now using glucometers for regular monitoring. The market has witnessed significant product innovations, exemplified by the FDA clearance of Dexcom G7 in December 2022 for adults and children aged two and above. These advanced systems offer features such as real-time monitoring, predictive alerts, and improved accuracy, addressing the evolving needs of both patients and healthcare providers.
The industry is witnessing a shift towards integrated diabetes management devices, combining monitoring devices with insulin delivery systems and digital health platforms. Recent developments include the emergence of non-invasive monitoring technologies, with several companies working on innovative solutions using radio waves, light sensors, and other advanced technologies. The market is also seeing increased focus on pediatric solutions, with manufacturers expanding their product offerings to cater to younger patient populations, supported by clinical trials and regulatory approvals for various age groups.
North America Blood Glucose Monitoring Market Trends
Rising Prevalence of Diabetes and Obesity
The increasing prevalence of diabetes and obesity continues to be a primary driver for the North American blood glucose monitoring market. According to the American Diabetes Association, as of 2022, approximately 122 million Americans have diabetes or prediabetes, with about 1.5 million new diabetes diagnoses occurring annually. This substantial patient population requires regular blood glucose measurement, creating a sustained demand for monitoring devices. The situation is similarly concerning in Canada, where Diabetes Canada reported in 2022 that 11.7 million Canadians are living with diabetes or prediabetes, with about 27% of the adult population living with obesity and 36% being overweight.
The correlation between obesity and Type 2 diabetes has become increasingly evident, with lifestyle changes and reduced physical activity contributing to higher diagnosis rates. The management of diabetes requires consistent blood sugar monitoring to prevent complications such as cardiovascular diseases, blood disorders, blindness, and kidney disorders. Healthcare providers are increasingly emphasizing the importance of regular monitoring, particularly for patients with Type 1 diabetes or severe Type 2 diabetes who are on insulin therapy, driving the demand for both self-monitoring blood glucose devices and continuous glucose monitoring systems.
Technological Advancements in Monitoring Devices
The blood glucose monitoring market is experiencing significant transformation through technological innovations that enhance user experience and monitoring accuracy. In 2023, the industry witnessed groundbreaking developments in continuous glucose monitoring (CGM) systems, with devices becoming smaller, more accurate, and more user-friendly. For instance, Abbott's FreeStyle Libre 3 system represents a significant advancement as the world's smallest and thinnest CGM sensor, while Dexcom's G7 offers enhanced accuracy and user interface improvements. These innovations are making glucose monitoring more convenient and accessible for patients, driving increased adoption rates.
The emergence of non-invasive glucose monitoring technologies represents another significant advancement driving market growth. Several companies are developing revolutionary monitoring solutions, including wristband-based systems using miniaturized MRI-like technology, radio wave-based measurement devices, and nickel-sized needle-free CGMs. Companies like Life Plus are developing multi-parameter wearable devices that can monitor glucose levels alongside other vital signs, while startups such as AnnNIGM, Novio Sense, and GraphWear Technologies are exploring innovative approaches using sweat and tears for glucose detection through ultrasonic, electromagnetic, and thermal technologies. These advancements are particularly significant as they address patient concerns about traditional invasive monitoring methods.
Favorable Reimbursement Policies
The expansion of insurance coverage and reimbursement policies for blood glucose monitoring devices has become a crucial market driver in North America. In 2023, significant policy changes have improved access to these essential devices. The Centers for Medicare and Medicaid Services has modified coverage criteria for continuous glucose monitors, extending coverage to people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia. This expansion has made advanced monitoring technologies more accessible to a broader patient population, particularly benefiting those who previously found these devices financially out of reach.
Provincial governments in Canada have also implemented supportive reimbursement policies. The Ontario government's initiative to provide coverage for real-time continuous glucose monitors through the province's Assistive Devices Program represents a significant development. The program covers CGM devices and related supplies for eligible individuals with Type 1 diabetes who are at risk of severe hypoglycemia or unable to recognize hypoglycemia symptoms. Private insurance plans have also expanded their coverage, with many plans now including home diabetes monitoring devices such as glucometers and continuous glucose monitors, often requiring only minimal copayments from patients after meeting deductibles.
Growing Awareness and Education Initiatives
The increasing emphasis on diabetes education and awareness programs by healthcare organizations and government bodies is significantly driving the adoption of blood glucose monitoring devices. Organizations like Diabetes Canada have launched comprehensive campaigns such as "Let's End Diabetes Together," focusing on educating the public about proper diabetes management and the importance of regular glucose monitoring. These initiatives are particularly effective in reaching previously underserved populations and promoting the benefits of consistent glucose monitoring in preventing long-term complications.
Healthcare providers are receiving enhanced training and support to better guide patients in utilizing advanced monitoring technologies. The American Diabetes Association, National Academy of Medicine, NIH, CDC, and Centers for Medicare & Medicaid Services are collectively promoting an integrated model of care that emphasizes the importance of proper glucose monitoring. These organizations are undertaking initiatives to educate healthcare providers about adjusting antihyperglycemic medications in response to blood glucose readings and helping patients make healthy behavioral changes based on their monitoring results. The implementation of digital health platforms that allow patients to share their glucose data with healthcare providers has further enhanced the effectiveness of these educational initiatives, leading to better disease management outcomes.
Segment Analysis: By Type
Self-Monitoring Blood Glucose Devices Segment in North America Blood Glucose Monitoring Market
Self-monitoring blood glucose devices continue to dominate the North American blood glucose monitoring market, holding approximately 53% market share in 2024. This segment encompasses essential components including blood glucose meter devices, glucose test strips, and lancets, with test strips generating the highest revenue contribution. The segment's prominence is largely attributed to the widespread adoption of these devices for routine blood glucose testing, particularly among Type 2 diabetes patients. The accessibility, cost-effectiveness, and established reimbursement policies for these devices have contributed to their market leadership. Additionally, technological advancements in self-monitoring devices, including improved accuracy, faster results, and connectivity features for data sharing with healthcare providers, have helped maintain their strong market position.

Continuous Blood Glucose Monitoring Devices Segment in North America Blood Glucose Monitoring Market
The continuous glucose monitoring devices segment is experiencing remarkable growth, with an estimated growth rate of approximately 20% during 2024-2029. This exceptional growth is driven by increasing adoption of advanced diabetes management technologies, particularly among Type 1 diabetes patients and intensive insulin users. The segment's expansion is further supported by recent technological innovations, such as improved sensor accuracy, extended wear time, and enhanced connectivity features. The integration of CGM systems with insulin pumps, smartphones, and other digital health platforms has significantly improved patient convenience and treatment outcomes. Additionally, expanding insurance coverage and favorable reimbursement policies have made these devices more accessible to a broader patient population, contributing to their accelerated market growth.
North America Blood Glucose Monitoring Market Geography Segment Analysis
Blood Glucose Monitoring Market in the United States
The United States dominates the North American blood glucose monitoring market, commanding approximately 92% of the total market share in 2024. The country's market leadership is driven by its advanced healthcare infrastructure and high adoption rates of innovative glucose monitoring technologies. The presence of major market players and their continuous product launches, particularly in continuous glucose monitoring (CGM) devices, has significantly shaped the market landscape. The country's robust reimbursement framework, including coverage through Medicare and private insurance providers, has facilitated greater access to blood glucose monitoring devices. The market has seen particular growth in CGM devices, which accounted for a significant portion of the total market, while self-monitoring blood glucose testing devices maintained their strong presence in diabetes management protocols. The increasing prevalence of diabetes, coupled with growing awareness about the importance of regular glucose monitoring, continues to drive market expansion. The United States also leads in technological innovations, with several startups and established companies developing advanced monitoring solutions, including non-invasive glucose monitoring technologies.
Blood Glucose Monitoring Market in Canada
Canada represents one of the most dynamic markets in the North American region, with a projected growth rate of approximately 15% from 2024 to 2029. The country's healthcare system has demonstrated a strong commitment to diabetes management through comprehensive coverage policies and support programs. The Ontario government's initiative to provide coverage for real-time continuous glucose monitoring devices through the province's Assistive Devices Program has significantly improved accessibility to advanced monitoring technologies. The implementation of Diabetes 360 Degree, a nationwide strategy, has created a structured framework for diabetes management and monitoring. The country's approach to diabetes care emphasizes preventive measures and early detection, driving the adoption of monitoring devices. Canadian healthcare providers have increasingly integrated digital health solutions with glucose monitoring systems, enhancing patient care quality. The market has witnessed substantial growth in both basic glucose meters and advanced CGM systems, supported by favorable reimbursement policies and growing awareness among healthcare providers and patients. The collaboration between government bodies and diabetes care organizations has created a supportive ecosystem for market growth.
Blood Glucose Monitoring Market in Other Countries
The blood glucose monitoring market in other North American territories, including Caribbean nations and other regions, presents unique opportunities and challenges. These markets are characterized by varying levels of healthcare infrastructure development and different approaches to diabetes management. The increasing prevalence of diabetes in these regions, particularly in Caribbean countries, has prompted healthcare systems to enhance their diabetes care capabilities. Many of these markets are experiencing a transition in healthcare delivery models, with a growing focus on preventive care and regular monitoring. The adoption of blood sugar testing devices varies significantly across these regions, influenced by factors such as healthcare spending capacity, awareness levels, and accessibility to medical technologies. Some countries have implemented specific programs to improve access to diabetes care devices, while others are in the process of developing comprehensive diabetes management strategies. The market in these regions shows potential for growth, particularly as healthcare systems continue to evolve and modernize their approach to diabetes management. International healthcare organizations and device manufacturers are increasingly focusing on these markets, recognizing the need for improved diabetes care solutions.
North America Blood Glucose Monitoring Industry Overview
Top Companies in North America Blood Glucose Monitoring Market
The North American blood glucose monitoring market features prominent players like Abbott Diabetes Care, F. Hoffmann-La Roche, LifeScan, Dexcom, and Medtronic leading the competitive landscape. These companies are heavily investing in continuous glucose monitoring (CGM) technology development, with a particular focus on creating more accurate, user-friendly, and connected devices. Strategic partnerships with digital health platforms, healthcare providers, and technology companies have become increasingly common to enhance product offerings and expand market reach. Companies are prioritizing the development of integrated diabetes management solutions that combine monitoring devices with data analytics and mobile applications. The market is characterized by substantial investments in research and development to create innovative features such as extended sensor life, improved accuracy, and enhanced connectivity options. Additionally, manufacturers are focusing on expanding their distribution networks and implementing competitive pricing strategies to maintain their market positions.
Consolidated Market with Strong Innovation Focus
The blood glucose monitoring market in North America exhibits a highly consolidated structure dominated by multinational healthcare conglomerates with established brand recognition and extensive distribution networks. These major players leverage their substantial research and development capabilities, manufacturing scale, and strong financial positions to maintain their market leadership. The market demonstrates significant barriers to entry due to stringent regulatory requirements, high initial investment needs, and the importance of established relationships with healthcare providers and insurance companies. Smaller players typically focus on niche segments or specific technological innovations to compete effectively.
The competitive landscape is shaped by ongoing merger and acquisition activities, as larger companies seek to acquire innovative startups and technology firms to enhance their product portfolios and maintain competitive advantages. Strategic collaborations between medical device manufacturers and technology companies are becoming increasingly common, particularly in developing integrated digital health solutions. Regional players maintain their presence through specialized product offerings and strong local distribution networks, though they face increasing pressure from global leaders expanding their market presence.
Innovation and Integration Drive Future Success
Success in the glucose monitoring market increasingly depends on companies' ability to develop integrated solutions that combine accurate monitoring capabilities with comprehensive diabetes management features. Market leaders are focusing on expanding their product portfolios through internal development and strategic acquisitions, while also strengthening their relationships with healthcare providers and insurance companies. The ability to provide value-added services, such as data analytics and personalized patient support, is becoming crucial for maintaining a competitive advantage. Companies must also navigate evolving regulatory requirements while maintaining cost-effectiveness in their operations.
Emerging players can gain market share by focusing on technological innovations that address specific unmet needs in the market, such as improved accuracy, longer sensor life, or enhanced user convenience. Building strong distribution networks and establishing partnerships with established healthcare providers are essential strategies for market expansion. Companies must also consider the increasing importance of reimbursement coverage and insurance partnerships in driving product adoption. The market's future success factors include the ability to adapt to changing healthcare regulations, maintain competitive pricing strategies, and develop products that align with the growing trend toward personalized medicine and remote patient monitoring, including wearable glucose monitoring and smart glucose monitoring technologies.
North America Blood Glucose Monitoring Market Leaders
-
Dexcom
-
Johnson & Johnson
-
Medtronics
-
F. Hoffmann-La Roche AG
-
Abbott Diabetes Care
- *Disclaimer: Major Players sorted in no particular order

North America Blood Glucose Monitoring Market News
- March 2023: Modified Abbott CGM sensors scored FDA nod for use in automated insulin delivery systems.
- December 2022: Dexcom, a company that manufactures continuous glucose monitors (CGMs) for blood sugar management, announced the FDA approval for their next-generation product, the Dexcom G7 CGM. The G7 is approved for people with all types of diabetes from ages two years and older.
North America Blood Glucose Monitoring Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Device
- 5.1.1 Self-monitoring Blood Glucose Devices
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.1.2 Continuous Glucose Monitoring
- 5.1.2.1 Sensors
- 5.1.2.2 Durables
-
5.2 End User
- 5.2.1 Hospital/Clinics
- 5.2.2 Home/Personal
-
5.3 Geography
- 5.3.1 United States
- 5.3.2 Canada
- 5.3.3 Rest of North America
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Abbott Diabetes Care
- 7.1.2 F. Hoffmann-La Roche AG
- 7.1.3 Johnson & Johnson
- 7.1.4 Dexcom
- 7.1.5 Medtronic
- 7.1.6 Arkray
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 Agamatrix Inc.
- 7.1.9 Bionime Corporation
- 7.1.10 Acon
- 7.1.11 Medisana
- 7.1.12 Trivida
- 7.1.13 Rossmax
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Blood Glucose Monitoring Industry Segmentation
Although glucose meters are an excellent tool, it is important to occasionally monitor blood sugar levels more closely. A continuous glucose meter (CGM) gadget is one aid in this situation. Blood sugar levels are monitored day and night by this FDA-approved system. Every 5 to 15 minutes, it automatically takes readings. The North American blood glucose monitoring market is witnessing a market size of USD 10.3 billion in the current year. It is anticipated to register a CAGR of over 7% during the forecast period.
The North American glucose monitoring market is segmented by type (self-monitoring blood glucose (glucometer devices, test strips, and lancets) and continuous glucose monitoring (sensors and durables)) and geography (United States, Canada, and Rest of North America). The report offers market size and forecasts for all the above segments in value (USD) and volume (in units).
Device | Self-monitoring Blood Glucose Devices | Glucometer Devices | |
Test Strips | |||
Lancets | |||
Continuous Glucose Monitoring | Sensors | ||
Durables | |||
End User | Hospital/Clinics | ||
Home/Personal | |||
Geography | United States | ||
Canada | |||
Rest of North America |
North America Blood Glucose Monitoring Market Research Faqs
How big is the North America Blood Glucose Monitoring Market?
The North America Blood Glucose Monitoring Market size is expected to reach USD 17.55 billion in 2025 and grow at a CAGR of 13.13% to reach USD 32.51 billion by 2030.
What is the current North America Blood Glucose Monitoring Market size?
In 2025, the North America Blood Glucose Monitoring Market size is expected to reach USD 17.55 billion.
Who are the key players in North America Blood Glucose Monitoring Market?
Dexcom, Johnson & Johnson, Medtronics, F. Hoffmann-La Roche AG and Abbott Diabetes Care are the major companies operating in the North America Blood Glucose Monitoring Market.
What years does this North America Blood Glucose Monitoring Market cover, and what was the market size in 2024?
In 2024, the North America Blood Glucose Monitoring Market size was estimated at USD 15.25 billion. The report covers the North America Blood Glucose Monitoring Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Blood Glucose Monitoring Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
North America Blood Glucose Monitoring Market Research
Mordor Intelligence provides comprehensive insights into the blood glucose monitoring industry. We leverage our extensive expertise in diabetes care research and analysis. Our detailed report covers a wide range of technologies. These include traditional BGM systems and glucose meters, as well as advanced CGM solutions and wearable glucose monitoring devices. The analysis explores various aspects of blood sugar testing, such as glucose test strips, glucose testing supplies, and emerging smart glucose monitoring technologies. Stakeholders can access these detailed insights in an easy-to-download report PDF format.
The report offers invaluable insights for stakeholders across the blood glucose measurement value chain. It is beneficial for manufacturers of diabetes management devices and healthcare providers implementing glycemic monitoring solutions. Our analysis covers both invasive glucose monitoring systems and innovative SMBG technologies. It examines the evolving landscape of blood sugar monitoring practices. The comprehensive coverage includes detailed analysis of blood glucose testing methodologies, emerging trends in glucose monitoring, and technological advancements in blood glucose meter development. This enables stakeholders to make informed decisions based on robust market intelligence.